{
    "clinical_study": {
        "@rank": "75418", 
        "arm_group": {
            "arm_group_label": "Etravirine", 
            "description": "Patients having Acquired Immune Deficiency Syndrome (AIDS) will be taking etravirine as per recommended doses."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety data of etravirine in a natural clinical\n      practice."
        }, 
        "brief_title": "A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Intelence", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Acquired Immune Deficiency Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a non-interventional (a scientific study to make a clear and easy understanding of\n      the cause and effect relationship), prospective (in which the participants are first\n      identified and then followed forward as time passes), consecutive survey for collecting\n      safety and efficacy data of etravirine in treatment of Acquired Immune Deficiency Syndrome\n      (AIDS) in a natural clinical practice."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who are prescribed with etravirine for treatment of Acquired Immune\n             Deficiency Syndrome (AIDS)\n\n        Exclusion Criteria:\n\n          -  Known hypersensitivity to Intelence\n\n          -  Intelence coadministered with medicinal products that are highly dependent on CYP3A\n             and CYP2C9 for clearance\n\n          -  Patients with galactose intoralance, Lapp lactase deficiency, and glucose-galactose\n             malabsorption"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "The study population will include patients who are diagnosed with Acquired Immune\n        Deficiency Syndrome (AIDS), and who are prescribed with etravirine for treatment of AIDS."
            }
        }, 
        "enrollment": {
            "#text": "3000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01741844", 
            "org_study_id": "CR100806", 
            "secondary_id": [
                "TMC125HIV4017", 
                "Intelene PMS", 
                "ETR-C-11-KR-001-V04"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Etravirine", 
            "description": "This is an observational study. Etravirine 200 mg will be adminstered twice daily in patients with Acquired Immune Deficiency Syndrome (AIDS).", 
            "intervention_name": "No intervention", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Acquired Immune Deficiency Syndrome", 
            "TMC125", 
            "Etravirine", 
            "Intelence", 
            "AIDS"
        ], 
        "lastchanged_date": "May 12, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Dae-Gu", 
                    "country": "Korea, Republic of"
                }
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "Regulatory Post Marketing Surveillance of Intelence Tablet", 
        "overall_official": {
            "affiliation": "Janssen Korea, Ltd., Korea", 
            "last_name": "Janssen Korea, Ltd., Korea Clinical Trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Korea: Food and Drug Administration", 
                "Republic of Korea: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of patients with adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 30 days from end of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01741844"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of patients with viral load", 
                "safety_issue": "No", 
                "time_frame": "Screening, Week 12, Week 24"
            }, 
            {
                "measure": "Number of patients with CD4 T-cell count", 
                "safety_issue": "No", 
                "time_frame": "Screening, Week 12, Week 24"
            }
        ], 
        "source": "Janssen Korea, Ltd., Korea", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Janssen Korea, Ltd., Korea", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}